Since folks who have the APOE e4 gene variant appear to have a better risk of serious problems, the FDA endorses remaining tested with the gene variant before beginning treatment with lecanemab or donanemab. The extension review also evaluated CLARITY AD participants who had a delayed start out (individuals who https://napoleonx864vfq4.iyublog.com/profile